Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1995-09-21
1998-12-29
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514634, A61K 3165, A61K 31155
Patent
active
058542906
ABSTRACT:
Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
REFERENCES:
patent: 4847300 (1989-07-01), Arnsten et al.
Chappell et al, Derwent Drug File Abstracts, No. 95-27904, 1994.
Kunchandy et al, Chemical Abstracts, vol. 105, No. 23, abstract No. 203125d, 1986.
Hunt, Robert D. et al., Journal of The American Academy of Child Psychiatry, vol. 24, pp. 617-629 (1985).
Arnsten et al., ".alpha..sub.2 -Adrenergic Mechanisms in Prefrontal Cortex Associated with Cognitive Decline in Aged Nonhuman Primates", Science 230:1273-1276, 1985.
Arnsten et al., "Alpha-2 Adrenergic Agonists Decrease Distractibility in Aged Monkeys Performing the Delayed Response Task", Psychopharmacology 108:159-169, 1992.
Arnstein et al., "The Alpha-2 Adrenergic Agonist Guanfacine Improves Memory in Aged Monkeys Without Sedative or Hypotensive Side Effects: . . . ", The Journal of Neuroscience 8:4287-4298, 1988.
Arnsten et al., "Behavioral and Receptor Binding Analysis of The Quinoxaline (UK-14304): . . . ", Neuropharmacology 30:1279-1289, 1991.
Brown et al., ".alpha..sub.2 -Adrenoceptor Subtypes and Imidazoline-Like Binding Sites in The Rat Brain", British Journal of Pharamacology 99:803-809, 1990.
Chappel et al., "Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience", J. Am Acad Child & Adolescent Psychiatry 34:1140-1146, 1995.
Hunt et al., "An Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder", J. Am. Acad Child Adolescent Psychiatry 34:50-56, 1995.
Sorkin et al., "Guanfacine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in the Treatment of Hypertension", Drugs 31:301-336, 1986.
Steere et al., "The Alpha-2A Noradrenergic Agonist, Guanfacine, Improves Delayed Response Performance and Calms Behavior in Young Monkeys: . . . ", Soc. for Neurosci. Abstracts 20:831, 1994.3
Uhlen et al., "Delineation of Rat Kidney .alpha..sub.2A - and Computer Modelling . . . ", European Journal of Pharmacology 202:235-243, 1991.
Vigne et al., "Guanabenz, Guanochlor, Guanoxan and Idazoxan Bind with High Affinity to Non-adrenergic Sites in Pis Kidney Membranes", European Journal of Pharmacology 160:295-298, 1989.
Horrigan et al., "Guanfacine for Treatment of Attention-Deficit Hyperactivity Disorder in Boys", J. Child Adolesc. Psychopharm 5:215-223, 1995.
Kugler et al., "Differences in Psychic Performance with Guanfacine and Clonidine in Normotensive Subjects", Br. J. Clin. Pharmac., Supplement 1 10:71S-80S, 1980.
Arnsten Amy F. T.
Goldman-Rakic Patricia S.
Hunt Robert H.
Arnsten Amy F. T.
Goldman-Rakic Patricia
Hunt Robert H.
Jarvis William R. A.
LandOfFree
Use of guanfacine in the treatment of behavioral disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of guanfacine in the treatment of behavioral disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of guanfacine in the treatment of behavioral disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1425262